BioCentury
ARTICLE | Clinical News

Alder submits BLA for migraine therapy, raises $130M in follow-on

March 1, 2019 1:33 AM UTC

After submitting its first BLA to FDA on Feb. 22, Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) raised $130 million in a bumped-up follow-on late Feb. 27.

Alder submitted the BLA for eptinezumab, a mAb against calcitonin-related gene peptide (CGRP), to treat migraine. While several anti-CGRP therapies have been approved in the past year, Alder's is the only delivered via infusion. Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) are all injectable (see "Getting Ahead of Headache"; "FDA Approves Lilly's mAb to Prevent Migraine")...